TITLE:
Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)

CONDITION:
Neoplasms

INTERVENTION:
Farnesyl Protein Transferase Inhibitor

SUMMARY:

      The purpose of this study is to determine the safety and tolerability of an oral Farnesyl
      Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous
      docetaxel in cancer patients with advanced solid tumors.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion:

          -  Male or Female

          -  Measurable or evaluable disease

          -  No more than 2 prior chemotherapy regimens.

          -  Age greater than or equal to 18.

          -  Karnofsky Performance Status greater than or equal to 70%.

          -  Meets protocol requirements for specified laboratory values.

          -  No manifestations of a malabsorption syndrome.

          -  Written informed consent and cooperation of patient

          -  Appropriate use of effective contraception if of child-bearing potential.

        Exclusion:

          -  Acute or chronic leukemia or multiple myeloma.

          -  Evidence of 2 or more active malignancies, expect for in situ or adequately treated
             basal or squamous cell skin cancer.
      
